a Department of Pharmacy Practice , Texas Tech University Health Sciences Center , Dallas , TX , USA.
b North Texas Veterans Health Care System , Dallas , TX , USA.
Expert Opin Pharmacother. 2018 Sep;19(13):1489-1494. doi: 10.1080/14656566.2018.1519021. Epub 2018 Sep 10.
Methicillin-resistant Staphylococcus aureus (MRSA)is a common pathogen in acute bacterial skin and soft tissue infections (ABSSSIs), nosocomial pneumonia, bacteremia, endocarditis, as well as diabetic foot, bone, and joint infections. Areas covered: This review summarizes the randomized controlled trials that evaluated the clinical efficacy of tedizolid in ABSSSIs, which is currently the only United States Food and Drug Administration-labeled indication for tedizolid. Expert opinion: Tedizolid has several potential advantages over linezolid including once-daily dosing, shorter duration of therapy, and increased tolerability. However, its cost will likely limit its adoption for ABSSSIs with MRSA because other oxazolidinone antibiotics are available in less costly generic versions. Tedizolid is also currently being investigated for its use in other MRSA infections including nosocomial pneumonia as well as diabetic foot, bone, and joint infections and tedizolid's use in these disease states appears more promising. Potential indications for future clinical investigation of tedizolid's efficacy and safety include bacteremia and meningitis.
耐甲氧西林金黄色葡萄球菌（MRSA）是急性细菌性皮肤和软组织感染（ABSSSIs）、医院获得性肺炎、菌血症、心内膜炎以及糖尿病足、骨和关节感染的常见病原体。
本综述总结了评估替加环素治疗 ABSSSIs 的临床疗效的随机对照试验，这是替加环素目前在美国食品和药物管理局批准的唯一适应证。
替加环素有几个潜在的优势超过利奈唑胺，包括每日一次给药、治疗时间更短和更高的耐受性。然而，由于其他噁唑烷酮类抗生素以更便宜的仿制药形式存在，其成本可能会限制替加环素在治疗耐甲氧西林金黄色葡萄球菌 ABSSSIs 中的应用。替加环素目前也在研究用于治疗其他耐甲氧西林金黄色葡萄球菌感染，包括医院获得性肺炎以及糖尿病足、骨和关节感染，替加环素在这些疾病状态下的应用似乎更有前景。未来替加环素疗效和安全性的临床研究的潜在适应证包括菌血症和脑膜炎。
